MedTrace Logo

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

NCT02511184 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-07-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose . The Dose Expansion Phase will explore the safety, tolerability, and anti-tumor activity of the combination.

Conditions

  • ALK-positive Advanced NSCLC

Interventions

DRUG

Crizotinib

To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks

DRUG

Pembrolizumab

To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511184 on ClinicalTrials.gov